Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· June 1, 2026

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

View original at globenewswire.com

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib Agios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor Agreement diversifies Agios’ rare hematology portfolio with expansion into immune thrombocy…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Cevidoplenib is a next-generation SYK inhibitor uniquely designed to potentially offer improved tolerability and durability compared to first-generation SYK inhibitors; backed by clinically meaningful Phase 2 data, it has the opportunity to become a best-in-class treatment option for ITP.
60% confidence
Licensing cevidoplenib is a natural extension of Agios' therapeutic focus and expertise, expanding and diversifying the rare hematology portfolio into ITP, and aligns with the company's disciplined approach to capital allocation.
60% confidence
Agios continues to expect its 2026 operating expense guidance to be approximately flat compared to 2025, excluding the $25.0 million upfront payment to Oscotec.
60% confidence
Agios expects to advance cevidoplenib into Phase 3 development for ITP in the first half of 2028, following completion of additional chemistry, manufacturing, and controls (CMC) development work.
60% confidence
The most commonly reported treatment-related adverse events with cevidoplenib in Phase 2 included transient elevations in liver enzymes and gastrointestinal events, and no new safety signals were identified.
60% confidence
Globally, ITP affects an estimated 200,000 individuals, including 90,000 adults diagnosed in the U.S., of whom roughly 50,000 have chronic ITP requiring treatment, and approximately 24,000 do not respond to initial treatments.
60% confidence
The Phase 2 primary endpoint did not achieve statistical significance, but durable and clinically meaningful platelet responses were observed in the cevidoplenib arm compared with placebo across multiple secondary endpoints; cevidoplenib was well tolerated.
60% confidence
The license agreement unlocks up to $1 billion in peak U.S. sales potential for cevidoplenib.
60% confidence